CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
Expanded Partnership Provides Free Biochemical and Genetic Testing to Patients Enrolled in REVEAL CP Study and Expands Global No-Cost Testing Program to Additional Countries
CAMBRIDGE, Mass. and ROSTOCK, Germany and HEIDELBERG, Germany and BERLIN, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that
transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today that it has expanded its partnership with PTC
Therapeutics, Inc. The companies will work together in several new regions including many countries in Europe, the Middle East, and Latin America to provide genetic testing and 3-O-Methyldopa
(3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase (AADC) deficiency. AADC deficiency is a life-shortening, ultra-rare genetic disorder that causes
severe disability and ongoing physical and mental suffering from the first few months of life. In addition, CENTOGENE will now provide this testing and biomarker analytics for patients involved in
the REVEAL CP study, a screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy (CP) of unknown cause.
The REVEAL CP study will screen patients for AADC deficiency with CentoCard – CENTOGENE’s CE-labeled dried blood spot collection kit – by evaluating blood samples for above normal levels of 3-OMD. Patients with elevated 3-OMD will be further tested for decreased levels of AADC enzyme activity and the presence of variants in the DOPA decarboxylase (DDC) gene. Through the generation of insights from the study, CENTOGENE and PTC aim to shorten the diagnosis time for patients living with AADC deficiency and ultimately accelerate the discovery of potential treatment options for patients living with this rare genetic disorder.
Justin Bingham, CENTOGENE’s Senior Vice President of Business Development, stated, “We are pleased to expand our partnership with PTC to support the REVEAL CP study, a global screening study designed to determine the prevalence of AADC deficiency in patients with cerebral palsy of an unknown cause. Together, we will offer genetic testing and 3-OMD biomarker analytics and widen the geographical scope of the no cost testing program, all of which are critical steps as we work together to bring hope to patients living with this rare genetic disorder.”
Centogene Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de